Zeynep Eroglu, MD

Zeynep Eroglu, MD, is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine.

Articles

Dr Eroglu on the Role of Triplet vs Doublet Regimens in Melanoma With Symptomatic Brain Metastases

September 15th 2025

Zeynep Eroglu, MD, discusses the implications of using triplet vs doublet regimens in patients with melanoma who have symptomatic brain metastases.

Dr Eroglu on Safety Considerations for Encorafenib/Binimetinib/Nivolumab in BRAF V600+ Melanoma

August 13th 2025

Zeynep Eroglu, MD, discusses management strategies for safe and effective use of encorafenib, binimetinib,and nivolumab in BRAF V600–mutant melanoma.

Dr Eroglu on the Study of Encorafenib Plus Binimetinib/Nivolumab in BRAF V600+ Melanoma With Brain Metastases

August 12th 2025

Zeynep Eroglu, MD, discusses the rationale for evaluating encorafenib plus binimetinib and nivolumab in BRAF V600-mutant melanoma with brain metastases.

Dr Eroglu on Addressing Unmet Needs in Mutant Melanoma

May 1st 2024

Zeynep Eroglu, MD, discusses a phase 1/2 trial that evaluated ceritinib alone and in combination with trametinib in patients with mutant melanoma.

Dr Eroglu on Ceritinib With or Without Trametinib in Pretreated Advanced Melanoma

May 1st 2024

Zeynep Eroglu, MD, discusses the efficacy and safety of ceritinib as monotherapy and in combination with trametinib in pretreated advanced melanoma.

Dr Eroglu on Future Steps for Assessing Ceritinib Plus Trametinib in Metastatic Melanoma

April 26th 2024

Zeynep Eroglu, MD, discusses future steps for assessing ceritinib in combination with trametinib in patients with metastatic melanoma.

Dr Eroglu on the Safety Profile of Ceritinib Plus Trametinib in Advanced Melanoma

April 25th 2024

Zeynep Eroglu, MD, discusses the safety profile of ceritinib plus trametinib in pretreated metastatic melanoma.

Dr. Erogolu on the Rationale for Investigating Patterns in BRAF+ Metastatic Melanoma

June 28th 2022

Zeynep Eroglu, MD, discusses the rationale for investigating patterns of outcomes in patients with metastatic melanoma harboring BRAF mutations.

Dr. Eroglu on the Utilization of ctDNA in Melanoma

March 1st 2022

Zeynep Eroglu, MD, discusses the utilization of circulating tumor DNA in patients with melanoma.